Navigation Links
NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has formed NaZura BioHealth, a separate company established to focus on the development of Gut Sensory Modulators (GSM) including lead product Lovidia™, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet™, the company's proprietary delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

(Logo: http://photos.prnewswire.com/prnh/20130904/LA73683LOGO)

"We are separating the Lovidia and NewMet assets in order to maximize their value as we approach critical development milestones," said Alain D. Baron, M.D., president and chief executive officer of both NaZura BioHealth and Elcelyx Therapeutics. "NaZura BioHealth will commercialize Lovidia, a one-of-a-kind weight loss product with launch planned for early second quarter 2014, and Elcelyx Therapeutics will continue to advance NewMet for Type 2 diabetes."

Lovidia, a dietary supplement, is being developed with the level of rigor typical of pharmaceutical products. An early Lovidia prototype demonstrated statistically significant and progressive weight loss through 16 weeks in a randomized, placebo-controlled, double-blind clinical study. In 121 evaluable overweight or obese subjects, three times as many people lost 5% of their body weight compared to placebo. This was accomplished without diet or exercise modification and the tolerability and safety profile of the prototype was similar to placebo. In other short-term studies, preliminary formulations of Lovidia increased the body's food-driven production of natural satiety and gluco-regulatory gut
'/>"/>

SOURCE NaZura BioHealth, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
5. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
6. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
7. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
8. PTC Therapeutics to Present at Upcoming Investor Conferences
9. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
10. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
11. Echo Therapeutics Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... N.J. , Aug. 2 Octapharma ... from the U.S. Food and Drug Administration (FDA) ... the replacement therapy developed specifically for von Willebrand Disease (VWD). ... Products Development , which helps to advance the development of ...
... EMERYVILLE, Calif. , Aug. 2 Bionovo, ... results from studies in neurons of its drug candidate Menerba ... in the Public Library of Science (PLoS) One, describes a ... from stem cells, and express native estrogen receptors. Menerba, an ...
Cached Medicine Technology:FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 2FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 3FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 4FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 5Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 2Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 3Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 4
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Programming Announced in Lead Up to World AIDS Day (Dec. ... PARK, Calif., Nov. 26 For more than ten years, ... the U.S. and abroad to reach the public with information ... surrounding the disease. The Foundation,s media partnerships leverage significant ...
... 26, 2008 The American Society for Gastrointestinal ... in U.S. cancer deaths and incidence rates, with colorectal ... ASGE, representing the specialists in colorectal cancer screening, is ... among men and women dropped 4.3 percent per year ...
... of Matthew L. Myers President, Campaign for Tobacco-Free Kids ... 26 Guatemala,s Congress on November 24, 2008, approved ... places, including restaurants and bars, be 100 percent smoke-free. ... protecting the health of Guatemala,s 13 million residents and ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... of our genetic material--about 2%-- performs the crucial task scientists ... serve as a blueprint for the production of proteins, the ... of human DNA is converted into intermediary molecules called RNAs, ... , And what of the other 98% of the ...
... taste sensation of rats to sweet foods and drives ... neuroscientists. Findings from the Penn State study could uncover ... reveal how flab hooks the brain on sugary food., ... you tend to consume it in higher amounts," said ...
Cached Medicine News:Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 2Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 3Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 4Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 5Health News:ASGE encouraged by drop in colorectal cancer deaths 2Health News:Guatemala's Congress Takes Action to Save Lives By Approving Strong Smoke-free Legislation 2Health News:Guatemala's Congress Takes Action to Save Lives By Approving Strong Smoke-free Legislation 3Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs 2Health News:Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs 3Health News:Route to obesity passes through tongue 2Health News:Route to obesity passes through tongue 3
ReNu 1 Step Enzymatic Cleaner with ReNu Multi-Purpose Solution removes protein deposits while lenses are being disinfected. Its a one-step process that saves time. Removes stubborn deposits from dai...
...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... intraocular lenses. The instrument consists of a ... implant and divides the implant into two ... halves of the lens so that unwanted ... chamber is avoided. The instrument is passed ...
Medicine Products: